Close Menu

The Scientist profiles Mireille Gingras' company, HUYA Bioscience International, which focuses on finding early-stage drug compounds from China. HUYA, the article says, has a codevelopment model in which it licenses the compounds for development for Western markets and the Chinese company retains the rights to the Chinese market.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.